Update on Linezolid In Vitro Activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013 | Zendy

Rodrigo E. Mendes | Zendy; Patricia A. Hogan | Zendy; Jennifer M Streit | Zendy; Ronald N. Jones | Zendy; Robert K. Flamm | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Update on Linezolid In Vitro Activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013

Author(s) -

Rodrigo E. Mendes,

Patricia A. Hogan,

Jennifer M Streit,

Ronald N. Jones,

Robert K. Flamm

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.04784-14

Subject(s) - potency , linezolid , pharmacology , in vitro , medicine , biology , bacteria , biochemistry , genetics , staphylococcus aureus , vancomycin

Linezolid showed MIC50s and MIC90s of 1 μg/ml (for both) against Staphylococcus aureus. Two S. aureus strains exhibited higher MICs (4 to 8 μg/ml) caused by cfr and/or target site mutations, including the first detection of cfr in Poland. Linezolid (MIC50 and MIC90, 0.5 and 1 μg/ml) had potent MICs against coagulase-negative staphylococci (CoNS). Four CoNS had MICs of 16 to 128 μg/ml due to alterations in 23S rRNA and/or L3/L4. Linezolid inhibited all enterococci and streptococci at ≤2 μg/ml, except for one Enterococcus faecium strain (MIC, 8 μg/ml; G2576T [Escherichia coli numbering] mutation).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research